1345847-75-7

Basic information

• Product Name: 1-(phenylcarbamoyl)cyclopropanecarbonyl chloride
• Synonyms: 1-(phenylcarbamoyl)cyclopropanecarbonyl chloride
• CAS NO: 1345847-75-7
• Molecular Weight: 223.659
• Mol File: 1345847-75-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-(phenylcarbamoyl)cyclopropanecarbonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(phenylcarbamoyl)cyclopropanecarbonyl chloride(1345847-75-7)
• EPA Substance Registry System: 1-(phenylcarbamoyl)cyclopropanecarbonyl chloride(1345847-75-7)

Safety Data

• Hazardous Substances Data: 1345847-75-7(Hazardous Substances Data)

Upstream product

• 598-10-7 cyclopropane-1,1-dicarboxylic acid 
• 145591-80-6 1-(phenylcarbamoyl)cyclopropane-1-carboxylic acid 
• 1345847-73-5 methyl 1-(phenylcarbamoyl)cyclopropanecarboxylate 
• 113020-21-6 1,1-cyclopropanedicarboxylic acid monomethyl ester 
• 62-53-3 aniline 

Downstream Products

• 849221-94-9 N-{4-[6,7-dimethoxyquinolin-4-yl-oxy]phenyl}-N'-phenylcyclopropanedicarboxamide 
• 1195778-92-7 N-[4-({2-[(cyclopropylcarbonyl)amino]-1,3-benzothiazol-6-yl}oxy)-3-fluorophenyl]-N'-phenylcyclopropane-1,1-dicarboxamide 
• 1345847-85-9 N-(4-(2-chloropyridin-4-yloxy)-2,5-difluorophenyl)-N'-phenylcyclopropane-1,1-dicarboxamide 
• 1345847-87-1 N-(4-(2-acetamidopyridin-4-yloxy)-2,5-difluorophenyl)-N'-phenylcyclopropane-1,1-dicarboxamide 

Relevant articles and documents

Design, synthesis and structure-activity relationship studies of novel phenoxyacetamide-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes

The free fatty acid receptor 1 (FFA1) has attracted extensive attention as a novel antidiabetic target in the last decade. Several FFA1 agonists reported in the literature have been suffered from relatively high molecular weight and lipophilicity. We have previously reported the FFA1 agonist 1. Based on the common amide structural characteristic of SAR1 and NIH screened compound, we here describe the continued structure-activity exploration to decrease the molecular weight and lipophilicity of the compound 1 series by converting various amide linkers. All of these efforts lead to the discovery of the preferable lead compound 18, a compound with considerable agonistic activity, high LE and LLE values, lower lipophilicity than previously reported agonists, and appreciable efficacy on glucose tolerance in both normal and type 2 diabetic mice.

FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF

The present invention provides a fused heterocyclic derivative having a strong kinase inhibitory activity and use thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specificatio